Epitelyal over karsinomlarında PCNA ekspresyonu

AMAÇ: PCNA’nın immunohistokimyasal olarak saptanması hem aktif DNA replikasyonunu hem de karsinogenez ile sonuçlanan DNA hasarını göstermektedir. PCNA hematolojik maligniteler, gastrointestinal sistem maligniteleri, meme, cilt, akciğer ve üriner sistem malignitelerinde proliferasyon belirteci olarak başarılı bir şekilde kullanılmıştır. Bu çalışmada kolorektal ve mesane karsinomlarında proliferasyonu gösteren PCNA’nın, epitelyal over karsinomlarında tümör proliferatif indeksi olarak kullanabilirliğinin incelenmesi amaçlanmıştır. YÖNTEMLER: Yaşları 17-82 arasında, epitelyal over karsinom tanısı alan 60 olguya ait materyallerin rutin patolojik işlemlerden sonra streptoavidin-biotin ortamında, primer antikorları ile PCNA immünreaktivitesini ve PCNA indekslerini değerlendirilmiştir. BULGULAR: : PCNA immünreaktivitesi ve indeksleri ile epitelyal over karsinomları arasında stage, grade ve lenf nodu tutulumu ile korelasyon araştırılmıştır. Tümörlerin grade dağılımının % 26 (n=16) grade 1, % 31 (n=19) grade 2, % 43 (n=25) grade 3 olduğu belirlenmiştir. Histolojik tümör tipleri ile PCNA pozitifliği arasında anlamlı bir istatistiksel ilişki saptanamamıştır (p>0,05). PCNA indeksleri, müsinöz karsinomlarda seröz karsinomlara oranla anlamlı derecede yüksek bulunmuştur (p

PCNA expression in epithelial ovarian carcinomas

Objective: Immunohistochemical detection of PCNA shows active DNA replication and DNAdamage resulting in carcinogenesis as well. PCNA has been used successfully as a marker ofproliferation in hematologic malignancies, gastrointestinal malignancies, breast, skin, lung andurinary tract malignancies. In this study, it was aimed to determine the possibility of using PCNA,which shows proliferation in colorectal and bladder carcinomas, as tumor proliferation index inepithelial ovarian carcinomas. Method: Sixty patients, in the age of 17-82 diagnosed with epithelial ovarian carcinoma usingroutine pathologic materials after operations in streptoavidin-biotin medium, proliferating cellnuclear antigen immunoreactivity and PCNA indexes were evaluated with the primary antibodies. Results: The correlation between the epithelial ovarian carcinomas and PCNA immunoreactivityand indexes with the stage, grade and lymph node involvement was investigated. It wasdetermined that the grade distributions of tumors were 26 % (n = 16) as grade 1, % 31 (n = 19) asgrade 2 and 43% (n = 25) as grade 3. There was no statistically signifcant relationship betweenthe histological tumor types and PCNA positivity (p> 0,05). PCNA indexes were found signifcantly higher in mucinous carcinomas than in serous carcinoma (p

PDF

___

Dodd JK, Henry RJW, Tyler PP. Tumor immunology and other post defense mechanism. Gynecol Oncol, 1989; 16: 560-613.
Sciarra JJ, Knapp RC, Berhomitz RS. Naturel history and detection of ovarian cancer. Gynecol Obstet, 1984; 28: 1-14.
Yavuz H, Tezcan S, Erk A. Over karsinomları Kadın Genital kanserleri. 1978; Vol. 9, 385-438.
Scully RE. Tumors of the ovary and maldeveloped gonads. Washington DC, Armed Forces Institute of Pathology, 1979; 16, 235-9.
Julian CG, Goss J, Blanchard K, Woodruff JD. Biologic behavior of primary ovarian malignancy. Gynecol Oncol, 1974; 873-4.
Julian CG, Woodruff JD. The biological behavior of low grade papillary serous carcinoma of the ovary. Obstet Gynecol, 1972; 40: 860-7.
Genodry R, Poliakoff S, Rotmensch J, Rosenshein NB, Parmley TH, Woodruff JD. Primary papillary peritoneal neoplasia. Cancer, 1988; 62: 2212-22.
Bell DA. Ovarian surface epithelial-stromal tumors. Hum. Pathol, 1991; 22:750-62.
Yancih R, Ries LG and Yartes JW. Ovarian cancer in the elderly; an analysis of surveillance, epidemiology and results data. Am. J. Obs Gynecol, 1986; 154: 639-47.
Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Canc Res Clin Oncol, 2001; 127: 73-9.
Berek JS, Adashi EY, Hillard PA, Jones HW. Ovarian cancer. Novak’s Gynecology Textbook, 1996; 28, 987-1021.
Snider DD, Stuart GC, Nation JG and Robertson DI. Evaluation of surgical staging in stage 1 low malignant potential ovarian tumors. Gynecol Oncol, 1991; 40: 129-32.
Lewis E, Wallace WS. Radiologic Diagnosis of Ovarian Cancer. In: Piver MS, ed. Ovarian Malignancies. Edinburgh: Churchill Livingstone 1987: 59-80.
Sessa F, Bonato M, Bisoni D, Ranzani GN, Capella C. Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: a relationship with tumor phenotype and survivle. Eur J Histochem, 1998; 42: 67-76.
Bell DA. Ovarian surface epithelial stromal tumors. Hum Pathol, 1991; 22: 750-62.
Miyachi K, Fritzler MJ, Tan EN. Autoantibody to nuclear antigen in proliferatif marcers. J Immunology, 1978; 121: 2228-34.
Ogata K, Kurki P, Celic J. Monoclonal antibodies to a nuclear protein associated DNA replication. Exp Cell Res, 1986; 168: 476-86.
Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifcations and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology, 2000; 70(2): 209-62.
Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, et al. Histological classifcation of ovarian cancer. Med Electron Microsc, 2003; 36(1): 9-17.
Iachino C, Katsikoyiannis N, Dallera F. Assessment of proliferating cell nuclear antigen (PCNA) immunoreactivity in carcinomas. Patholocia, 1995; 87: 56-8.
Jaskulski D, Gatti C, Travali S, Calabretta B, Baserga R. Regulation of the proliferating cell nuclear antigen cyclin and thymidine kinase m RNA levels by growth factors. J Biol Chem, 1988; 25; 263(21): 10175-9.
Scott RJ, Hall PA, Haldane JS. A comparison of immunohistochemical markers of cell proliferating with experimentally determined growth fraction. J Pathol, 1991;165(2):173-8.
Smith LH, Oi RH. Detection of malignant ovarian neoplasms, a review of the literature. Detection of the patient at risk, clinical, radiological and cytological detection. Obstet Gynecol Surv, 1984; 39: 313-28.
Xue Y, Feng Y, Zhu G, Zhang X. Proliferatif activity in intraepithelial neoplasia and cervical carcinoma. C Med J, 1999; 112(4): 373-5.
Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Romanini C. Proliferatif cell nuclear antigen in endometrial carcinoma: pretreatment identifcation of high risk patients. Gynecol Oncol, 1996; 61(1): 16-21.
Wang X, Huang Z, Di W, Lin Q. Comparison of D&C and hysterectomy pathologic fndings in endometrial cancer patients. Arch Gynecol Obstet, 2005; 272(2): 136-41.
Nakano T, Enoki K, Nakashima M, Ishıkawa H, Ametani Y, Ohta S, Ohkuchi A, Satake S, Kojima Y, Funamoto H, Tateno M, Miwa A. Survival in patients with clear cell carcinoma of the ovary. Gan To Kagaku Ryoho, 1998; 25(1): 67-73.
Li JD, Li MD, Li YF, Huang X, Liu JH, Liu FY, Zhang CQ. Relationship between expressions of p53, c-erbB2 genes, proliferatif cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma. Ai Zheng, 2002; 21(3): 292-6.
Abike F, Zengeroglu S, Dünder İ. Epitelyal olmayan over kanserlerinde PCNA ekspresyonu ve prognoza etkileri. Turk Hij Den Biyol Derg, 2010;67(1):13-9.